Benitec Biopharma (BNTC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$12.8M

Net income growth (year over year)

−45.47%

Net margin

—

Return on equity

−33.21%

EPS (trailing twelve months)

−$0.98

Book value per share

$5.14

P/E (trailing twelve months)

—

Price to book

1.63

Debt to assets

3.07%

Payout ratio

—

Dividend yield

—

Company profile

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

• How do I buy stock in Benitec Biopharma (BNTC)?

  BNTC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.